Impaired proliferative response of Vα24 NKT cells from cancer patients against α-galactosylceramide

Journal of Immunology

Volumn 168, Issue 12, 2002, Pages 6494-6499

  Yanagisawa, Kazuhiko ^a   Seino, Ken Ichiro ^a   Ishikawa, Yuriko ^a   Nozue, Mutsumi ^a   Todoroki, Takeshi ^a   Fukao, Katashi ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GALACTOSYLCERAMIDE; GALACTOSYLCERAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER PATIENT; CELL ACTIVITY; CELL CULTURE; CELL FRACTIONATION; CELL PROLIFERATION; CELL SELECTION; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; IMMUNOTHERAPY; IN VITRO STUDY; NATURAL KILLER CELL; PRIORITY JOURNAL; TARGET CELL;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; CELLS, CULTURED; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; FLOW CYTOMETRY; GALACTOSYLCERAMIDES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; INTERLEUKIN-2; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASMS; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; T-LYMPHOCYTE SUBSETS;

EID: 0037097678     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. + T cell populations
2. + thymocytes selected by MHC class I molecules
3. Selective reduction of T cells bearing invariant Vα24 JαQ antigen receptor in patients with systemic sclerosis
4. Requirement for Vα14 NKT cells in IL-12-mediated rejection of tumors
5. Requirement for natural killer T (NKT) cells in the induction of allograft tolerance
6. Natural killer-like nonspecific tumor cell lysis mediated by specific ligand-activated Vα14 NKT cells
7. Inhibition of experimental tumor metastasis by dendritic cells pulsed with α-galactosylceramide
8. CD1d-mediated recognition of an galactosylceramide by natural killer T cells is highly conserved through mammalian evolution
9. CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells
10. A novel recognition motif of human NKT antigen receptor for a grycolipid ligand
11. Antitumor cytotoxicity mediated by ligand-activated human Vα24 NKT cells
12. Enhancing T lymphocytes from tumor-bearing mice suppress host resistance to a syngeneic tumor
13. + T cell function
14. Plasma transforming growth factor-β1 in patients with hepatocellular carcinoma: Comparison with chronic liver diseases
15. Transforming growth factor-β-induced inhibition of T cell function: Susceptibility difference in T cells of various phenotypes and functions and its relevance to immunosuppression in tumor-bearing state
16. Loss of IFN-γ production by invariant NKT cells in advanced cancer
17. Cytotoxic γδ or αβT cells with a natural killer cell maker, CD56, induced from human peripheral blood lymphocytes by a combination of IL-12 and IL-2
18. Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells
19. Identification and natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes
20. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells
21. The molecular control of cell division, differentiation, commitment and maturation in haematopoietic cells
22. Induction of differentiation of pre-NKT cells to mature Vα14 NKT cells by granulocyte/macrophage colony-stimulating factor
23. int cells in the lymph nodes and other peripheral organs of mice carrying the lpr gene
24. Expansion of extrathymic T cells as well as granulocytes in the liver and other organs of granulocyte-colony stimulating factor transgenic mice: Why they lost the ability of hybrid resistance
25. Varying expression levels of colony stimulating factor receptors in disease states and different leukocytes
26. Alternative splicing form of the human CD1D gene in mononuclear cells
27. KRN7000, an NKT cell enhancer, in patients with solid tumors: A phase study of the EORTC BTDG